Cognition Therapeutics
Cognition Therapeutics develops zervimesine (CT1812), an oral small molecule targeting toxic oligomers in neurodegenerative diseases.
424B3Sep 11Latest SEC filing
Aug 6Latest story
August 2026
Sign inSign inCognition Therapeutics develops zervimesine (CT1812), an oral small molecule targeting toxic oligomers in neurodegenerative diseases.